Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941684 | 1.00 | LMNA (0.36) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL723573 | 1.00 | LMNA (0.36) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL27522036 | 1.00 | LMNA (0.36) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL4880937 | 0.89 | — | — | |
| SCHEMBL1785079 | 0.89 | — | — | |
| SCHEMBL1783279 | 0.89 | — | — | |
| SCHEMBL15846054 | 0.84 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL16798768 | 0.83 | PDE4A (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL29162767 | 0.83 | PDE4A (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5859311 | 0.83 | PDE4A (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401361-B2 | Intracellular organelle peptide targeted enzyme substrates | MARKER GENE TECHNOLOGIES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180120317-A1 | INTRACELLULAR ORGANELLE PEPTIDE TARGETED ENZYME SUBSTRATES | MARKER GENE TECHNOLOGIES, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9841426-B2 | Intracellular organelle peptide targeted enzyme substrates | MARKER GENE TECHNOLOGIES, INC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150219654-A1 | INTRACELLULAR ORGANELLE PEPTIDE TARGETED ENZYME SUBSTRATES | MARKER GENE TECHNOLOGIES, INC. | 2015-08-06 | — | — | US | disclosed |
| EP-1439187-B1 | O2-ARYLATED OR O2-GLYCOSYLATED 1-SUBSTITUTED DIAZEN-1-IUM-1,2-DIOLATES AND O2-SUBSTITUTED 1- (2-CARBOXYLATO)PYRROLIDIN-1-YL DIAZEN-1-IUM-1,2-DIOLATES | US HEALTH (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2298358-A1 | Methods for delivery of nucleic acids | Alnylam Pharmaceuticals Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2292630-A1 | O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009138195-A2 | USE OF THIOPHENE GLYCOSIDE DERIVATIVES FOR PRODUCING MEDICAMENTS FOR TREATMENT OF HYPERTENSION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090163436-A1 | METHODS FOR DELIVERY OF NUCLEIC ACIDS | NUCLEONICS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-7081524-B2 | O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-07-25 | — | — | US | disclosed |
| US-6610660-B1 | (2,4-dinitrophenyl)-1-(N,N-diethylamino)diazen-1 -ium-1,2-diolate, used as nitric oxide generators for prevention and therapy of cardiovascular disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-08-26 | — | — | US | disclosed |
| US-20030147845-A1 | O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl]diazen-1-ium-1,2-diolates | GOVERNMENT OF THE USA, THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2002080980-A1 | LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM | ISIS INNOVATION LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| EP-0929538-A1 | O?2 -ARYLATED OR O?2 -GLYCOSYLATED 1-SUBSTITUTED DIAZEN-1-IUM-1,2-DIOLATES AND O?2 -SUBSTITUTED 1- (2-CARBOXYLATO)PYRROLIDIN-1-YL]DIAZEN-1-IUM-1,2-DIOLATES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013358-A1 | O2-ARYLATED OR O2-GLYCOSYLATED 1-SUBSTITUTED DIAZEN-1-IUM-1,2-DIOLATES AND O2-SUBSTITUTED 1-[(2-CARBOXYLATO)PYRROLIDIN-1-YL]DIAZEN-1-IUM-1,2-DIOLATES | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5633261-A | ANTITUMOR AGENTS | TORONTO RESEARCH CHEMICALS, INC. (CA) | 1997-05-27 | — | — | US | disclosed |
| US-5621106-A | REACTING WITH DIALKYLTIN OXIDE; ACYLATION; ALKYLATION | TORONTO RESEARCH CHEMICALS, INC. (CA) | 1997-04-15 | — | — | US | disclosed |
| US-5466809-A | From aminomannose, antitumor agents, castanospermine | TORONTO RESEARCH CHEMICALS, INC. (CA) | 1995-11-14 | — | — | US | disclosed |
| EP-0613478-A1 | IMMUNOSTIMULATING SWAINSONINE ANALOGS | TORONTO RESEARCH CHEMICALS INC. (CA) | 1994-09-07 | — | — | EP | disclosed |
| WO-1993009117-A1 | IMMUNOSTIMULATING SWAINSONINE ANALOGS | TORONTO RESEARCH CHEMICALS INC. (CA) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030147845-A1 | O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl]diazen-1-ium-1,2-diolates | NOS1, NOX1, NOS2 | LMNA 4601/4885L3MBTL1 3174/4885PDE4A 1545/4885 |
| US-10401361-B2 | Intracellular organelle peptide targeted enzyme substrates | GLG1, GBA3, MIA3 | LMNA 2023/4885L3MBTL1 3595/4885PDE4A 2843/4885 |
| US-20180120317-A1 | INTRACELLULAR ORGANELLE PEPTIDE TARGETED ENZYME SUBSTRATES | GLG1, GBA3, MIA3 | LMNA 2023/4885L3MBTL1 3595/4885PDE4A 2843/4885 |
| US-20150219654-A1 | INTRACELLULAR ORGANELLE PEPTIDE TARGETED ENZYME SUBSTRATES | GLG1, GBA3, MIA3 | LMNA 2023/4885L3MBTL1 3595/4885PDE4A 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.